HEMATOLOGY

In the prospective, double-blind, phase 2 randomized controlled trial, in which investigators evaluated the efficacy and safety of topical ruxolitinib, a novel gene signature was identified.

In a 16 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee has voted yes to future approvals of PI3K inhibitors being supported by randomized data given observed toxicities in the drug class, research showing a detriment in OS, a narrow range between effective, and toxic doses.

During a Targeted Oncology case-based roundtable event, Matthew A. Davids, MD, MMSc, discussed key considerations for prophylaxis and the use of rasburicase in managing tumor lysis syndrome.

Magrolimab clinical trials including patients with myelodysplastic syndrome and acute myeloid leukemia may continue now that the FDA has lifted a partial clinical hold.

During a presentation, Paul G. Richardson, MD, talked about the shift from triplet combination therapies toward quadruplet combinations for the treatment of multiple myeloma.

Guenther Koehne, MD, PhD, discusses the exciting presentations going on at the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

In pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia who had a non-response to blinatumomab and a high-disease burden, worse outcomes were observed , according to retrospective research.

Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.

A brief discussion on the risk of treatment-induced damage when managing patients with chronic graft-versus-host disease.

Having reviewed approved treatment options for steroid-refractory, chronic GVHD, experts discuss how they would address this patient scenario.

Considerations for belumosudil and axatilimab as treatment options for steroid-refractory chronic graft-versus-host disease.

A review of treatment options approved for steroid-refractory chronic graft-versus-host disease starting with ibrutinib and ruxolitinib.

Shared insight on how to distinguish chronic GVHD from acute GVHD, as well as utilize appropriate methods to risk stratify disease.

Shifting their focus to chronic graft-versus-host disease, experts review a patient scenario and discuss the challenges in early intervention.

AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.

Experts review the prognosis of a patient with acute graft-versus-host disease and identify ways to optimize their treatment strategies.

A panel of experts discuss systemic therapy to manage a patient with acute graft-versus-host disease.

Centering discussion on a patient scenario of acute graft-versus-host disease, participants discuss nuance in disease symptomology and patient education.

Expert perspectives on the nature and occurrence of graft-versus-host disease alongside available prophylactic regimens.

Treatment with AUTO1, an investigational CD19-targeted chimeric antigen receptor T-cell therapy, is being evaluated in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Results from the phase 1b EQUATE study were favorable enough to initiate a phase 3 study, which will test itolizumab for the frontline treatment of acute graft-versus-host disease..

The FDA is no longer conducting a speedy review of the supplemental biologics license application for luspatercept-aamt as treatment for anemia in adults with non-transfusion-dependent beta thalassemia.

Researchers found that depletion of naïve T cells from peripheral blood stem cell allografts results in very low incidences of severe acute and chronic graft-versus-host disease without reduced risk of relapse or nonrelapse mortality.

Despite its infrequency, early cardiac toxicity may occur more often in patients who received cyclophosphamide-based graft-versus-host disease prophylaxis and those who have a prior history of cardiac disease.